Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.
Gómez Tejeda Zañudo J, Barroso-Sousa R, Jain E, Jin Q, Li T, Buendia-Buendia JE, Pereslete A, Abravanel DL, Ferreira AR, Wrabel E, Helvie K, Hughes ME, Partridge AH, Overmoyer B, Lin NU, Tayob N, Tolaney SM, Wagle N.
Gómez Tejeda Zañudo J, et al. Among authors: hughes me.
Nat Commun. 2024 Mar 19;15(1):2446. doi: 10.1038/s41467-024-45835-6.
Nat Commun. 2024.
PMID: 38503755
Free PMC article.
Clinical Trial.